July 10, 2012
Some of the fastest evolving tools for evaluating the molecular and genetic underpinnings of disease are proving difficult to wield. Despite their great potential, it has been difficult to translate data generated through genomics, proteomics, and metabolomics into actual improvements in patient care. In hopes of speeding that progress, The Institute of Medicine in March ... Read more
June 12, 2012
From the moment of its inception, the Human Genome Project was expected to yield substantial benefits in diagnostics. But the genome is only part of the story. Equally important are the mRNA transcripts that carry out the genome’s orders, the proteins they encode, and ultimately, the metabolites upon which they act. Today, thanks to rapid ... Read more
May 22, 2012
Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva. “A major goal of lung cancer treatment is to tailor the treatment to the individual,” says Dr Fiona Blackhall from The Christie ... Read more
January 16, 2012
This study found that choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer (NSCLC). The four- to six-week survival advantage held up in a sensitivity analysis involving 10,000 simulations. Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in ... Read more
December 13, 2011
The use of Biodesix’ predictive cancer therapy assay VeriStrat has been validated in a Phase III trial originally carried out to evaluate GlaxoSmithKline’s Tykerb®/Tyverb® (lapatinib) as an addition to Novartis’ Femara® (letrozole) in breast cancer patients. Data from the trial demonstrated that VeriStrat could be used to identify a group of patients with worse progression-free survival (PFS) when treated with Femara alone, independent of Her2 ... Read more
April 4, 2011
Blood is a readily available and rich source of biomarkers that have the potential for use in diagnostics and companion diagnostics development, disease characterization and monitoring, and predictive drug response and toxicity analysis. Serum profiling using a variety of techniques to identify disease- or treatment-related proteins, antibodies, or oligonucleotides is leading to the identification of ... Read more
March 2, 2011
Personalized medicine, one goal of molecular diagnostics that is already being clinically realized, offers the opportunity to treat individuals on a case-by-case basis with greater efficacy and efficiency than ever before.
Molecular diagnostics is heading the way of personalized medicine, aiming to help physicians devise particular treatment plans for individuals based on their genetic makeup.
“This is ... Read more
January 24, 2011
As Biodesix continues clinical validation and commercialization of its test to predict patient response to therapies for non-small cell lung cancer, it is looking to forge pharmaceutical partnerships to increase adoption of the test. The company is in the midst of conducting a trial in Italy to determine whether the test can determine which NSCLC ... Read more
August 27, 2010
Blood analysis good at predicting how tumours will respond; Proteomic test useful when doctors have no tumour tissue
LONDON, April 30 (Reuters) – Testing for specific cancer protein markers in lung cancer patients’ blood helps find those more likely to respond to Tarceva, a drug sold by Roche (ROG.VX) and OSI Pharmaceuticals OSIP.O, data showed on ... Read more
May 21, 2010
CBSA’s May BioBreakfast allowed two of Colorado’s 2009 Bioscience success stories to share their stories. First up was Paul Beresford of Biodesix, a company playing in the diagnostic space. Dr. Beresford spoke to the attendees about Biodesix’s successful introduction of VeriStrat, a proteomic serum test used in lung cancer.
For Customer Support, call: (866) 432-5930